{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:10:41Z","timestamp":1794654641158,"version":"4.9.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Project of Nanchang Science and Technology Bureau","award":["JX20190078"],"award-info":[{"award-number":["JX20190078"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Currently, there are a number of sodium glucose co-transport-2 (SGLT2) inhibitors that are under development or in clinical trials. Prior meta-analyses had established the safety and efficacy of SGLT2 inhibitors in type 1 diabetes mellitus (T1DM), but with low level of evidences and inconsistent conclusions. However, recently many new randomized clinical trials (RCTs) have been published, we hence try to design a study protocol to assess the effect of SGLT2 inhibitors on cardiovascular events via a comprehensive meta-analysis of data from much more RCTs, including sensitivity and subgroup analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines to conduct this meta-analysis. Two investigators will perform a systematic search of scientific literature in the databases (from conception through June 12, 2021), including PubMed, Embase, and Cochrane Central Register of Controlled Trials. This meta-analysis will be conducted using RevMan statistical software. The risk of bias for each included study will be assessed using the Cochrane Risk of Bias Assessment Tool.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Our protocol is conceived to test the hypothesis that SGLT2 inhibitors could lead to better outcomes in patients presenting with T1DM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration number:<\/jats:title>\n            <jats:p>10.17605\/OSF.IO\/ZD8WX.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026417","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T17:37:37Z","timestamp":1625679457000},"page":"e26417","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy of sodium glucose co-transport-2 inhibitors on glycemic control for patients with type 1 diabetes mellitus"],"prefix":"10.1097","volume":"100","author":[{"given":"Yajie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6841-4459","authenticated-orcid":false,"given":"Yanan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40265-018-0901-y","article-title":"The potential role of SGLT2 inhibitors in the treatment of Type 1 diabetes mellitus","volume":"78","author":"Fattah","year":"2018","journal-title":"Drugs"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e3207","DOI":"10.1002\/dmrr.3207","article-title":"The remission phase in type 1 diabetes: changing epidemiology, definitions, and emerging immuno-metabolic mechanisms","volume":"36","author":"Zhong","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2337\/diacare.28.1.186","article-title":"Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association","volume":"28","author":"Silverstein","year":"2005","journal-title":"Diabetes Care"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in Type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.jcjd.2015.09.001","article-title":"The role of the kidney and SGLT2 inhibitors in Type 2 diabetes","volume":"39","author":"Katz","year":"2015","journal-title":"Can J Diabetes"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/1060028017710481","article-title":"SGLT-2 inhibitors: is there a role in Type 1 diabetes mellitus management?","volume":"51","author":"Ahmed-Sarwar","year":"2017","journal-title":"Ann Pharmacother"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"44128","DOI":"10.1038\/srep44128","article-title":"The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"22","DOI":"10.24920\/J1001-9242.2007.003","article-title":"Efficacy and safety of SGLT2 inhibitors in patients with Type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"32","author":"Yang","year":"2017","journal-title":"Chin Med Sci J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:34:02Z","timestamp":1746340442000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026417"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":10,"journal-issue":{"issue":"27","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026417","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"2021-05-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}